Literature DB >> 22664634

Be it resolved that in the modern era, the best method for dose escalation is brachytherapy: The con position.

D Andrew Loblaw1.   

Abstract

Year:  2012        PMID： 22664634      PMCID： PMC3367018          DOI： 10.5489/cuaj.12122

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  22 in total

1.  The dosimetric quality of brachytherapy implants in patients with small prostate volume depends on the experience of the brachytherapy team.

Authors:  Hong-Wei Liu; Kyle Malkoske; David Sasaki; Jeff Bews; Alain Demers; Zoann Nugent; Aldrich Ong; Bashir Bashir; Tarek Dufan; Patrick Cho; Darryl Drachenberg; Amit Chowdhury
Journal:  Brachytherapy       Date:  2010-05-31       Impact factor: 2.362

2.  Androgen deprivation therapy for prostate cancer-review of indications in 2010.

Authors:  H Quon; D A Loblaw
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

3.  Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate.

Authors:  Jinka R Sathya; Ian R Davis; Jim A Julian; Qing Guo; Dean Daya; Ian S Dayes; Himu R Lukka; Mark Levine
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

4.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

Authors:  Stephanie T H Peeters; Wilma D Heemsbergen; Peter C M Koper; Wim L J van Putten; Annerie Slot; Michel F H Dielwart; Johannes M G Bonfrer; Luca Incrocci; Joos V Lebesque
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

5.  Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.

Authors:  Peter J Hoskin; Ana M Rojas; Peter J Bownes; Gerry J Lowe; Peter J Ostler; Linda Bryant
Journal:  Radiother Oncol       Date:  2012-02-16       Impact factor: 6.280

6.  Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.

Authors:  Thomas P Boike; Yair Lotan; L Chinsoo Cho; Jeffrey Brindle; Paul DeRose; Xian-Jin Xie; Jingsheng Yan; Ryan Foster; David Pistenmaa; Alida Perkins; Susan Cooley; Robert Timmerman
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

7.  The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.

Authors:  Howard D Thames; Deborah Kuban; Larry B Levy; Eric M Horwitz; Patrick Kupelian; Alvaro Martinez; Jeffrey Michalski; Thomas Pisansky; Howard Sandler; William Shipley; Michael Zelefsky; Anthony Zietman
Journal:  Radiother Oncol       Date:  2010-04-17       Impact factor: 6.280

8.  Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial.

Authors:  Eric E Yeoh; Rochelle J Botten; Julie Butters; Addolorata C Di Matteo; Richard H Holloway; Jack Fowler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-08       Impact factor: 7.038

9.  Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.

Authors:  Raymond Miralbell; Stephen A Roberts; Eduardo Zubizarreta; Jolyon H Hendry
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-15       Impact factor: 7.038

10.  Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis.

Authors:  Tom Pickles; Mira Keyes; W James Morris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.